Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.49 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.45 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5510635 | 0.88 | ALDH1A1 (0.68) | MAPTRAB9AALDH1A1HPGDPTPN1 | |
| SCHEMBL3418331 | 0.87 | ALDH1A1 (0.70) | ALDH1A1HPGDPTPN1PTPN11KDM4E | |
| SCHEMBL3904837 | 0.87 | PTPN1 (0.67) | MAPTALDH1A1HPGDPTPN1PTPN11 | |
| SCHEMBL3900126 | 0.85 | KMT2A (0.57) | MAPTRAB9AALDH1A1HPGDPTPN1 | |
| SCHEMBL3896317 | 0.83 | ALDH1A1 (0.60) | MAPTALDH1A1HPGDPTPN1PTPN11 | |
| SCHEMBL5510786 | 0.81 | MEN1 (0.69) | MAPTRAB9AALDH1A1HPGDLMNA | |
| SCHEMBL11457930 | 0.80 | MEN1 (0.61) | MAPTRAB9AALDH1A1HPGDPTPN1 | |
| SCHEMBL5512059 | 0.80 | ALDH1A1 (0.53) | MAPTALDH1A1HPGDPTPN1PTPN11 | |
| SCHEMBL1772679 | 0.79 | ALDH1A1 (0.84) | ALDH1A1HPGDPTPN1PTPN11KDM4E | |
| SCHEMBL4874209 | 0.78 | ALDH1A1 (0.54) | MAPTRAB9AALDH1A1HPGDPTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070203117-A1 | modulators of nicotinic and/or of monoamine receptors; as diagnostic tools or monitoring agents; for in vivo neuroimaging in labeled/unlabelled forms; inflammation, pain, neurodegenerative disorders; cholinergic ligands;5-(4-Benzoylamino-phenyl)-furan-2-carboxylic acid(1-aza-bicyclo[2.2.2]oct-3-yl)-amide | NEUROSEARCH A/S (DK) | 2007-08-30 | — | — | US | claimed |
| EP-1751150-A2 | NOVEL AZABICYCLIC ARYL DERIVATIVES | NEUROSEARCH A/S (DK) | 2007-02-14 | — | — | EP | claimed |
| WO-2005111033-A2 | NOVEL AZABICYCLIC ARYL DERIVATIVES | NEUROSEARCH A/S (DK) | 2005-11-24 | — | — | WO | claimed |
| US-20070203117-A1 | modulators of nicotinic and/or of monoamine receptors; as diagnostic tools or monitoring agents; for in vivo neuroimaging in labeled/unlabelled forms; inflammation, pain, neurodegenerative disorders; cholinergic ligands;5-(4-Benzoylamino-phenyl)-furan-2-carboxylic acid(1-aza-bicyclo[2.2.2]oct-3-yl)-amide | NEUROSEARCH A/S (DK) | 2007-08-30 | — | — | US | disclosed |
| EP-1751150-A2 | NOVEL AZABICYCLIC ARYL DERIVATIVES | NEUROSEARCH A/S (DK) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005111033-A2 | NOVEL AZABICYCLIC ARYL DERIVATIVES | NEUROSEARCH A/S (DK) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070203117-A1 | modulators of nicotinic and/or of monoamine receptors; as diagnostic tools or monitoring agents; for in vivo neuroimaging in labeled/unlabelled forms; inflammation, pain, neurodegenerative disorders; cholinergic ligands;5-(4-Benzoylamino-phenyl)-furan-2-carboxylic acid(1-aza-bicyclo[2.2.2]oct-3-yl)-amide | CHRNA5, CHRNA2, CHRNA6 | MAPT 1063/4885RAB9A 3434/4885ALDH1A1 923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.